MV Mateos
MV Mateos
Verified email at
Cited by
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ...
New England Journal of Medicine 359 (9), 906-917, 2008
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ...
New England Journal of Medicine 372 (2), 142-152, 2015
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...
New England Journal of Medicine 375 (8), 754-766, 2016
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hajek, ...
Leukemia 23 (2), 215-224, 2009
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ...
The Lancet 387 (10027), 1551-1560, 2016
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide …
MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ...
The lancet oncology 11 (10), 934-941, 2010
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ...
Blood 108 (7), 2165-2172, 2006
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in …
MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ...
Journal of Clinical Oncology 28 (13), 2259-2266, 2010
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis …
E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ...
Blood, The Journal of the American Society of Hematology 110 (7), 2586-2592, 2007
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ...
New England Journal of Medicine 378 (6), 518-528, 2018
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood 127 (24), 2955-2962, 2016
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ...
Annals of Oncology 28 (suppl_4), iv52-iv61, 2017
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ...
Blood 120 (8), 1589-1596, 2012
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ...
Blood 125 (13), 2068-2074, 2015
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Perez, MA Montalbán, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
MV Mateos, MT Hernández, P Giraldo, J de la Rubia, F de Arriba, ...
New England Journal of Medicine 369 (5), 438-447, 2013
The system can't perform the operation now. Try again later.
Articles 1–20